A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception
NCT ID: NCT00185419
Last Updated: 2009-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
842 participants
INTERVENTIONAL
2003-11-30
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
YAZ, Oral Contraceptive Registration in China
NCT00819312
Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers
NCT00624130
Efficacy and Safety Oral Contraceptive Study
NCT00185484
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
NCT02710708
Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females
NCT00745901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Yasmin
30 µg ethinylestradiol, 3mg drospirenone
Arm 2
Marvelon
30 µg ethinylestradiol, 150 µg desogestrel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yasmin
30 µg ethinylestradiol, 3mg drospirenone
Marvelon
30 µg ethinylestradiol, 150 µg desogestrel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer Schering Pharma AG
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ask Contact, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
308062
Identifier Type: -
Identifier Source: secondary_id
91330
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.